Receptor activity-modifying protein 1 increases baroreflex sensitivity and attenuates angiotensin-induced hypertension

Hypertension

Volumn 55, Issue 3, 2010, Pages 627-635

  Sabharwal, Rasna ^a   Zhang, Zhongming ^a   Lu, Yongjun ^a   Abboud, Francois M ^a   Russo, Andrew F ^a   Chapleau, Mark W ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Baroreflex sensitivity; Blood pressure; Calcitonin gene related peptide; Heart rate variability; Parasympathetic nerve activity; Transgenic mice

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN II; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; RECEPTOR ACTIVITY MODIFYING PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE VARIABILITY; CONTROLLED STUDY; HEART RATE; HEART RATE VARIABILITY; HYPERTENSION; LOCOMOTION; MALE; MEAN ARTERIAL PRESSURE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRESSOR RESPONSE; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; TELEMETRY; UPREGULATION;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AUTONOMIC NERVOUS SYSTEM DISEASES; BAROREFLEX; BLOOD PRESSURE; CALCITONIN GENE-RELATED PEPTIDE; GENE EXPRESSION; HEART RATE; HUMANS; HYPERTENSION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LOSARTAN; MALE; MEMBRANE PROTEINS; MICE; MICE, TRANSGENIC; PARASYMPATHETIC NERVOUS SYSTEM; PHENOTYPE; RECEPTOR, ANGIOTENSIN, TYPE 1; VASOCONSTRICTOR AGENTS;

EID: 77149151574     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.109.148171     Document Type: Article

References (49)

1. Brain SD, Grant AD. Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol Rev. 2004;84:903-934.
2. van Rossum D, Hanisch UK, Quirion R. Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neurosci Biobehav Rev. 1997;21:649-678.
3. Portaluppi F, Vergnani L, Margutti A, Ambrosio MR, Bondanelli M, Trasforini G, Rossi R, Degli Uberti EC. Modulatory effect of the renin-angiotensin system on the plasma levels of calcitonin gene-related peptide in normal man. J Clin Endocrinol Metab. 1993;77:816-820.
4. Pan CS, Jiang W, Wu SY, Zhao J, Pang YZ, Tang CS, Qi YF. Potentiated response to adrenomedullin in myocardia and aortas in spontaneously hypertensive rat. Basic Res Cardiol. 2006;101:193-203.
5. Supowit SC, Guraraj A, Ramana CV, Westlund KN, DiPette DJ. Enhanced neuronal expression of calcitonin gene-related peptide in mineralcorticoid-salt hypertension. Hypertension. 1995;25:1333-1338.
6. Li J, Wang DH. Development of angiotensin II-induced hypertension: role of CGRP and its receptor. J Hypertens. 2005;23:113-118.
7. Wang Y, Wang DH. Prevention of endothelin-1-induced increases in blood pressure: role of endogenous CGRP. Am J Physiol Heart Circ Physiol. 2004;287:H1868-H1874.
8. Supowit SC, Zhao H, Hallman DM, DiPette DJ. Calcitonin gene-related peptide is a depressor of deoxycorticosterone-salt hypertension in the rat. Hypertension. 1997;29:945-950. (Pubitemid 27152463)
9. Kummer W. Retrograde neuronal labeling and double-staining immuno-histochemistry of tachykinin-and calcitonin gene-related peptide-immunoreactive pathways in the carotid sinus nerve of the guinea pig. J Auton Nerv Syst. 1988;23:131-141.
10. Skofitsch G, Jacobowitz DM. Calcitonin gene-related peptide: detailed immunohistochemical distribution in the central nervous system. Peptides. 1985;6:721-745. (Pubitemid 16195056)
11. Inagaki S, Kito S, Kubota Y, Girgis S, Hillyard CJ, MacIntyre I. Autoradiographic localization of calcitonin gene-related peptide binding sites in human and rat brains. Brain Res. 1986;374:287-298.
12. Fisher LA, Kikkawa DO, Rivier JE, Amara SG, Evans RM, Rosenfeld MG, Vale WW, Brown MR. Stimulation of noradrenergic sympathetic outflow by calcitonin gene-related peptide. Nature. 1983;305:534-536.
13. Nguyen KQ, Sills MA, Jacobowitz DM. Cardiovascular effects produced by microinjection of calcitonin gene-related peptide into the rat central amygdaloid nucleus. Peptides. 1986;7:337-339.
14. Hasegawa T, Yokotani K, Okuma Y, Manabe M, Hirakawa M, Osumi Y. Microinjection of a-calcitonin gene-related peptide into the hypothalamus activates sympathetic outflow in rats. Jap J Pharmacol. 1993; 61:325-332.
15. Vallejo M, Lightman S, Marshall I. Central cardiovascular effects of calcitonin gene-related peptide: interaction with noradrenaline in the nucleus tractus solitarius of rats. Exp Brain Res. 1988;70:221-224.
16. Okamoto H, Hoka S, Kawasaki T, Sato M, Yoshitake J. Effects of CGRP on baroreflex control of heart rate and renal sympathetic nerve activity in rabbits. Am J Physiol Regul Integr Comp Physiol. 1992;263:R874-R879.
17. Kim S, Ouchi Y, Sekiguchi H, Fujikawa H, Shimada K, Yagi K. Endogenous calcitonin gene-related peptide modulates tachycardiac but not bradycardiac baroreflex in rats. Am J Physiol Heart Circ Physiol. 1998; 274:H1489-H1494.
18. Kirchheim HR. Systemic arterial baroreceptor reflexes. Physiol Rev. 1976;56:100-176.
19. La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction; ATRAMI (Autonomic Tone and Reflexes after Myocardial Infarction) Investigators. Lancet. 1998; 351:478-484.
20. Tatasciore A, Renda G, Zimarino M, Soccio M, Bilo G, Parati G, Schillaci G, De Caterina R. Awake systolic blood pressure variability correlates with target-organ damage in hypertensive subjects. Hypertension. 2007;50: 325-332.
21. Oh-hashi Y, Shindo T, Kurihara Y, Imai T, Wang Y, Morita H, Imai Y, Kayaba Y, Nishimatsu H, Suematsu Y, Hirata Y, Yazaki Y, Nagai R, Kuwaki T, Kurihara H. Elevated sympathetic nervous activity in mice deficient in aCGRP. Circ Res. 2001;89:983-990.
22. Gangula PR, Zhao H, Supowit SC, Wimalawansa SJ, Dipette DJ, Westlund KN, Gagel RF, Yallampalli C. Increased blood pressure in a-calcitonin gene-related peptide/calcitonin gene knockout mice. Hypertension. 2000;35: 470-475.
23. Lu JT, Son YJ, Lee J, Jetton TL, Shiota M, Moscoso L, Niswender KD, Loewy AD, Magnuson MA, Sanes JR, Emeson RB. Mice lacking a-calcitonin gene-related peptide exhibit normal cardiovascular regulation and neuromuscular development. Mol Cell Neurosci. 1999;14: 99-120.
24. Juaneda C, Dumont Y, Quirion R. The molecular pharmacology of CGRP and related peptide receptor subtypes. Trends Pharmacol Sci. 2000;21: 432-438.
25. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG, Foord SM. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature. 1998;393: 333-339.
26. Zhang Z, Winborn CS, Marquez de Prado B, Russo AF. Sensitization of calcitonin gene-related peptide receptors by receptor activity-modifying protein-1 in the trigeminal ganglion. J Neurosci. 2007;27:2693-2703.
27. Zhang Z, Dickerson IM, Russo AF. Calcitonin gene-related peptide receptor activation by receptor activity-modifying protein-1 gene transfer to vascular smooth muscle cells. Endocrinology. 2006;147:1932-1940.
28. Chrissobolis S, Zhang Z, Lynch CM, Kinzenbaw DA, Russo AF, Faraci FM. Receptor activity modifying protein-1 (RAMP1) overexpression selectively enhances calcitonin gene-related peptide-induced vasodilation [abstract]. FASEB J. 2008;22:1151.3.
29. Butz GM, Davisson RL. Long-term telemetric measurement of cardiovascular parameters in awake mice: a physiological genomics tool. Physiol Genomics. 2001;5:89-97.
30. Laude D, Baudrie V, Elghozi JL. Applicability of recent methods used to estimate spontaneous baroreflex sensitivity to resting mice. Am J Physiol Regul Integr Comp Physiol. 2008;294:R142-R150.
31. Thireau J, Zhang BL, Poisson D, Babuty D. Heart rate variability in mice: a theoretical and practical guide. Exp Physiol. 2008;93:83-94.
32. Lakso M, Pichel JG, Gorman JR, Sauer B, Okamoto Y, Lee E, Alt FW, Westphal H. Efficient in vivo manipulation of mouse genomic sequences at the zygote stage. Proc Natl Acad Sci USA. 1996;93:5860-5865.
33. Tsujikawa K, Yayama K, Hayashi T, Matsushita H, Yamaguchi T, Shigeno T, Ogitani Y, Hirayama M, Kato T, Fukada S, Takatori S, Kawasaki H, Okamoto H, Ikawa M, Okabe M, Yamamoto H. Hypertension and dysregulated proinflammatory cytokine production in receptor activity-modifying protein 1-deficient mice. Proc Natl Acad Sci USA. 2007;104:16702-16707.
34. Kawada N, Imai E, Karber A, Welch WJ, Wilcox CS. A mouse model of angiotensin II slow pressor response: role of oxidative stress. J Am Soc Nephrol. 2002;13:2860-2868.
35. Li Q, Dale WE, Hasser EM, Blaine EH. Acute and chronic angiotensin hypertension: neural and nonneural components, time course, and dose dependency. Am J Physiol Regul Integr Comp Physiol. 1996;271: R200-R207.
36. Fink GD, Bruner CA, Mangiapane ML. Area postrema is critical for angiotensin-induced hypertension in rats. Hypertension. 1987;9:355-361.
37. Zimmerman MC, Lazartigues E, Sharma RV, Davisson RL. Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system. Circ Res. 2004;95:210-216.
38. Laragh JH, Baer L, Brunner HR, Buhler FR, Sealey JE, Vaughan ED Jr. Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med. 1972;52:633-652.
39. Gao L, Wang W, Li Y-L, Schultz HD, Liu D, Cornish KG, Zucker IH. Superoxide mediates sympathoexcitation in heart failure: Roles of angio-tensin II and NAD(P)H oxidase. Circ Res. 2004;95:937-944.
40. Christopoulos A, Christopoulos G, Morfis M, Udawela M, Laburthe M, Couvineau A, Kuwasako K, Tilakaratne N, Sexton PM. Novel receptor partners and function of receptor activity-modifying proteins. J Biol Chem. 2003;278:3293-3297.
41. Muff R, Buhlmann N, Fischer JA, Born W. An amylin receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying proteins-1 or-3. Endocrinology. 1999;140:2924-2927.
42. Roh J, Chang CL, Bhalla A, Klein C, Hsu SYT. Intermedin is a calcito-nin/calcitonin gene-related peptide family peptide acting through the calcitonin receptor-like receptor/receptor activity-modifying protein receptor complexes. J Biol Chem. 2004;279:7264-7274.
43. Buhlmann N, Leuthauser K, Muff R, Fischer JA, Born W. A receptor activity modifying protein (RAMP)2-dependent adrenomedullin receptor is a calcitonin gene-related peptide receptor when coexpressed with human RAMP1. Endocrinology. 1999;140:2883-2890.
44. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Telera MP, Pede S, Gattobigio R, Porcellati C. Adverse prognostic value of a blunted cir-cadian rhythm of heart rate in essential hypertension. J Hypertens. 1998; 16:1335-1343.
45. Cueille C, Pidoux E, de Vernejoul M-C, Ventura-Clapier R, Garel J-M. Increased myocardial expression of RAMP1 and RAMP3 in rats with chronic heart failure. Biochem Biophys Res Comm. 2002;294:340-346.
46. Dong YL, Green KE, Vegiragu S, Hankins GD, Martin E, Chauhan M, Thota C, Yallampalli C. Evidence for decreased calcitonin gene-related peptide (CGRP) receptors and compromised responsiveness to CGRP of fetoplacental vessels in preeclamptic pregnancies. J Clin Endocrinol Metab. 2005;90:2336-2343.
47. Nagae T, Mukoyama M, Sugawara A, Mori K, Yahata K, Kasahara M, Suganami T, Makino H, Fujinaga Y, Yoshioka T, Tanaka I, Nakao K. Rat receptor-activity- modifying proteins (RAMPs) for adrenomedullin/CGRP receptor: cloning and upregulation in obstructive nephropathy. Biochem Biophys Res Commun. 2000;270:89-93.
48. Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004;350:1104-1110.
49. Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, Leibensperger H, Froman S, Assaid C, Lines C, Koppen H, Winner PK. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008;372:2115-2123.